Intellia Therapeutics (NTLA) Non-Current Deffered Revenue (2015 - 2025)

Intellia Therapeutics (NTLA) has reported Non-Current Deffered Revenue for 11 consecutive years, with $12.5 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Non-Current Deffered Revenue fell 44.53% year-over-year to $12.5 million; the TTM figure through Sep 2025 stood at $12.5 million (down 44.53% YoY), while the FY2024 annual figure was $18.3 million, down 53.01% from the prior year.
• Non-Current Deffered Revenue held at $12.5 million in Q3 2025 per NTLA's latest filing, from $12.5 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $63.5 million in Q4 2021 and bottomed at $12.5 million in Q2 2025.
• Historically, Non-Current Deffered Revenue has averaged $29.6 million across 5 years, with a median of $25.7 million in 2022.
• Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue surged 251.99% — and 2023, when it tumbled 71.99%.
• Intellia Therapeutics' Non-Current Deffered Revenue stood at $63.5 million in 2021, then slumped by 68.6% to $19.9 million in 2022, then soared by 94.93% to $38.9 million in 2023, then tumbled by 53.01% to $18.3 million in 2024, then slumped by 31.32% to $12.5 million in 2025.
• Business Quant data shows NTLA's Non-Current Deffered Revenue at $12.5 million in Q3 2025, $12.5 million in Q2 2025, and $13.2 million in Q1 2025.